Association of ABO Blood Groups and Early T2-Inflammatory Biomarkers in Pediatric Asthma: A Case–Control Study from Najaf, Iraq
DOI:
https://doi.org/10.63939/5hx76648Keywords:
ABO Blood Groups, Inflammatory Biomarkers, Pediatric AsthmaAbstract
Background: Asthma is a long-term inflammatory disease of the airways that is prevalent mostly in children, and its early diagnosis is not easy because of the similarity of the disease to other respiratory diseases. Objective: This paper examines the interaction between the ABO blood groups and the early diagnostic biomarkers- FeNO, serum IgE, periostin, TSLP, and T2 cytokines in asthma in children. Methods: A total of 50 children with established asthma were recruited as well as 30 children with intermittent asthma-like symptoms recruited in Najaf teaching hospitals. Results: Asthmatic children, compared to the intermittent group, had significant increases in FeNO, IgE, periostin, TSLP, and T2 cytokines. There was a greater prevalence of blood group A in asthmatic children. The findings point to the possibility of using blood group distribution in conjunction with T2-inflammation biomarkers to improve the ability to detect asthma early and phenotype it in children. Conclusions : High levels of FeNO, IgE, periostin, TSLP, and T2 cytokines have a strong association with pediatric asthma. A- Splenic blood group A seems to be more prevalent in asthmatic children. The incorporation of the biomarkers with the ABO phenotyping can help to enhance early diagnosis of asthma.
Downloads
References
1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention: 2024 Update. GINA Guidelines 2024. https://ginasthma.org/2024-report/
2. Martinez FD. The origins of asthma: Predicting the path to prevention. N Engl J Med., 2020;382(20):1930–1942. doi:10.1056/NEJMra1900816.
3. Dweik RA, Boggs PB, Erzurum SC, et al; ATS Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med., 2011;184(5):602–615. doi:10.1164/rccm.9120-11ST.
4. Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol., 2015;15(1):57–65. doi:10.1038/nri3786.
5. Agache I, Beltran J, Akdis CA, et al. EAACI Biologicals Guidelines—Recommendations for severe asthma. Allergy. 2022;77(5):1470–1486. doi:10.1111/all.15229.
6. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy., 2018;48(10):1307–1316. doi:10.1111/cea.13218.
7. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Nat Rev Dis Primers., 2018;4:1–19. doi:10.1038/s41572-018-0001-8.
8. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF. Exploring the effects of biologic therapy on biomarkers in asthma. J Allergy Clin Immunol., 2018;141(6):2052–2064. doi:10.1016/j.jaci.2017.10.043.
9. Cooling L. Blood transfusion and pneumonia in critically ill patients: what’s the link? Transfus Med Rev., 2015;29(3):159–199. doi:10.1016/j.tmrv.2015.03.002.
10. Xu X, Pan J, Cai L, et al. Blood eosinophil levels and asthma outcomes: insights from clinical cohorts. Allergy. 2022;77(4):1124–1135. doi:10.1111/all.15010.
11. Talaat RM, Elshabrawy OA, Mohamed AA. Asthma control and inhaler technique assessment in adult patients. J Asthma., 2021;58(1):1–8. doi:10.1080/02770903.2020.1732635.
12. Lee WK, Chung JH, Song JS, et al. FeNO and asthma control evaluation. Ann Allergy Asthma Immunol., 2020;124(1):75–82. doi:10.1016/j.anai.2019.10.017.
13. Khatri S, Moore W, Gibson PG. Biomarker-based management strategies in severe asthma. Am J Respir Crit Care Med.., 2019;200(10):1281–1285. doi:10.1164/rccm.201905-0999ED.
14. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy in uncontrolled asthma. N Engl J Med., 2014;371(13):1085–1095. doi:10.1056/NEJMoa1403290.
15. Malinovschi A, Janson C, Lisspers K, et al. Blood eosinophils and asthma phenotypes. Clin Exp Allergy., 2016;46(7):907–920. doi:10.1111/cea.12733.
16. Petsky HL, Kew KM, Turner C, Milford CA, Lasserson TJ. Tailored interventions based on biomarkers for asthma management. Cochrane Database Syst Rev., 2016;2016(2): CD011484.
17. Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-IL-5 monoclonal antibody in asthma. N Engl J Med., 2014;370(23):2102–2110. doi:10.1056/NEJMoa1405809.
18. Corren J. Targeting IL-5 in asthma: clinical perspectives. J Allergy Clin Immunol.., 2019;143(5):1783–1794. doi:10.1016/j.jaci.2019.03.042.
19. Busse W, Dahlén SE, Jenkins C, et al. Omalizumab, anti-IgE therapy for allergic asthma. Lancet. 2013;382(9901):989–999. doi:10.1016/S0140-6736(13)61116-7.
20. Mayr FB, Spiel AO, Leitner E, et al. Transfusion practices and outcomes in critically ill patients. Blood Transfus., 2017;15(5):441–448. doi:10.2450/2017.0054-17.
21. Jensen GL, Carlson K, Cockerham B, et al. Clinical nutrition and inflammation in chronic disease. Int Arch Allergy Immunol., 2021;182(10):1053–1061. doi:10.1159/000518486.
22. Khan N, Smith M, Ali R, et al. Asthma phenotypes and treatment responses in children: a multicenter cohort. J Pediatr Allergy Immunol., 2023;34(1):1–9. doi:10.1111/pai.13829.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Journal of Progressive Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
